Unfractionated Heparin Market - Regional Analysis
On the basis of region, the unfractionated heparin market is segmented into North America,
Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a leading
position in the global unfractionated heparin market, owing to increasing prevalence of deep
venous thromboembolism and Pulmonary Embolism in the region. For instance, according to the
Centers for Disease Control and Prevention (CDC), February 2018 data findings, around 60,000
to 100,000 people are estimated to die due to DVT/PE, in the U.S. Moreover, 10% to 30% of
people die within one month from diagnosis. Additionally, according to the same source,
around 5% to 8% of the U.S. population has one of several genetic risk factors, such as
inherited thrombophilias, which increases the risk for thrombosis.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1672
Unfractionated Heparin Market Competitive Landscape
Some of the key players operating in the unfractionated heparin market are B. Braun Melsungen
AG, Pfizer, Inc., Baxter International Inc., Siemens Ag, Sagent Pharmaceuticals, Inc., and LEO
Pharma A/S.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com